RECRUITING

Stress and Pain in People Living With HIV

Talk to us

Conditions

HIVDepressionCannabis Use DisorderStressPain

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a basic human experimental study utilizing 4 groups of individuals with and without HIV and complex morbidities of cannabis use disorder and major depression who will participate in 2 sessions of the Yale Pain Stress Task (YPST) and follow-up phase to assess drug use and mood symptoms.

Official Title

Stress-immune Mechanisms for People Living With HIV, CUD and Depression

Quick Facts

Study Start:2025-01-16
Study Completion:2030-01-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06784908

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 68 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * good health as verified by screening examination
  2. * Able to read English and complete study evaluations and provide informed written and verbal consent. Additional criteria PLWH
  3. * HIV-1 lab test positive
  4. * undetectable viral load
  5. * good ART adherence
  6. * CB positive urine toxicology
  7. * meet DSM-5 criteria for CUD and MDD as assessed using SCID-I. HC
  8. * HIV-1 test negative
  9. * urine toxicology negative
  10. * no major medical and psychiatric diagnoses based on DSM-V.
  11. * HIV-1 test positive
  12. * urine toxicology negative
  13. * no major medical and psychiatric diagnoses based on DSM-V.
  14. * HIV-1 test negative
  15. * urine toxicology positive
  16. * meet DSM-5 criteria for CUD and MDD as assessed using SCID-I
  1. * meet primary, current moderate and severe criteria for other SUD including cocaine, alcohol, opiates, sedatives, nicotine
  2. * current use or past history of cocaine or opioid use disorder
  3. * history of any psychotic disorder
  4. * current diagnoses of bipolar disorder and PTSD
  5. * psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania)
  6. * significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology that would interfere with study participation
  7. * medications with known central effects on HPA axis and cytokines/immune function
  8. * women who are pregnant, nursing or those using hormonal birth control that affect HPA axis cortisol responses.

Contacts and Locations

Study Contact

Rachel Hart, MA
CONTACT
203-737-4791
Rachel.hart@yale.edu

Principal Investigator

Rajita Sinha, Ph.D.
PRINCIPAL_INVESTIGATOR
Yale University

Study Locations (Sites)

The Yale Stress Center
New Haven, Connecticut, 06519
United States

Collaborators and Investigators

Sponsor: Yale University

  • Rajita Sinha, Ph.D., PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-16
Study Completion Date2030-01-31

Study Record Updates

Study Start Date2025-01-16
Study Completion Date2030-01-31

Terms related to this study

Additional Relevant MeSH Terms

  • HIV
  • Depression
  • Cannabis Use Disorder
  • Stress
  • Pain